The company reported net sales of Eylea in the United States of $402 million for the fourth quarter of 2013, compared to $276 million in the fourth quarter of 2012. In 2013, net sales of Eylea in the United States were $1.409 billion, compared to $838 million in 2012.

"We are pleased with our performance in 2013, with strong Eylea sales growth globally and continued progress in our pipeline, as well as the launch of our new research initiative in the field of genomics through our Regeneron Genetics Center," said Leonard S. Schleifer, MD, PhD, president and CEO of Regeneron. "Looking forward, in 2014 we expect Eylea to continue to grow through demographic and geographic expansion, as well as potential approvals in new indications, such as diabetic macular edema.”

Net sales of Eylea outside of the United States for the treatment of wet AMD and macular edema following central retinal vein occlusion, which are commercialized by Bayer HealthCare, were $184 million for the fourth quarter of 2013 and $472 million for the full year, compared to $19 million in both the fourth quarter and full year of 2012.